Evidence map›Paper›PMID 26976645›Full record

ArticleMolecular and cellular biology2016

RNA Activation of the Vascular Endothelial Growth Factor Gene (VEGF) Promoter by Double-Stranded RNA and Hypoxia: Role of Noncoding VEGF Promoter Transcripts.

Pascal Lopez, Kay-Dietrich Wagner, Paul Hofman, Emmanuel Van Obberghen

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Pascal LopezINSERM, U1081, Institute for Research on Cancer and Aging of Nice, Aging and Diabetes Team, Nice, France CNRS, UMR 7284, Institute for Research on Cancer and Aging of Nice, Nice, France Faculty of Medicine, Institute for Research on Cancer and Aging of Nice, University Nice-Sophia-Antipolis, Nice, France pascal.lopez@unice.fr.
Kay-Dietrich WagnerINSERM, U1081, Institute for Research on Cancer and Aging of Nice, Aging and Diabetes Team, Nice, France CNRS, UMR 7284, Institute for Research on Cancer and Aging of Nice, Nice, France Faculty of Medicine, Institute for Research on Cancer and Aging of Nice, University Nice-Sophia-Antipolis, Nice, France.
Paul HofmanINSERM, U1081, Institute for Research on Cancer and Aging of Nice, Aging and Diabetes Team, Nice, France CNRS, UMR 7284, Institute for Research on Cancer and Aging of Nice, Nice, France Laboratory of Clinical and Experimental Pathology and Hospital-Related Biobank (BB-0033-00025), University Hospital, Nice, France FHU OncoAge, University Nice-Sophia-Antipolis, Nice, France.
Emmanuel Van ObberghenINSERM, U1081, Institute for Research on Cancer and Aging of Nice, Aging and Diabetes Team, Nice, France CNRS, UMR 7284, Institute for Research on Cancer and Aging of Nice, Nice, France Faculty of Medicine, Institute for Research on Cancer and Aging of Nice, University Nice-Sophia-Antipolis, Nice, France FHU OncoAge, University Nice-Sophia-Antipolis, Nice, France Clinical Chemistry Laboratory, University Hospital, Nice, France.
Inserm · FRCentre National de la Recherche Scientifique · FRInstitut de Recherche sur le Cancer et le Vieillissement de Nice · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA activation (RNAa) is a gene regulation process in which promoter-targeted short double-stranded RNAs (dsRNAs) or microRNAs (miRs) induce target gene expression at the transcriptional level. Here, we investigate the presence of cryptic promoter transcripts within the VEGF promoter. Single-strand sense and antisense noncoding vascular endothelial growth factor (NcVEGF) promoter transcripts are identified, and their respective expression is studied in cells transfected with a VEGF promoter targeted dsRNA, namely, dsVEGF706, in hypoxic cells and in human malignant lung tissues. Interestingly, in dsVEGF706-transfected, as well as in hypoxic cells, NcVEGF expression levels increase coordinately with coding VEGF expression. Ago2 interaction with both sense and antisense NcVEGFs is increased in hypoxic cells, whereas in dsVEGF706-transfected cells, Ago2 and the antisense strand of the dsRNA interact specifically with the sense NcVEGF transcript. Furthermore, both dsVEGF706 and ectopic NcVEGF transcripts are able to activate the VEGF promoter endogenously present or in a reporter construct. Finally, using small interfering RNA targeting Ago2, we show that RNAa plays a role in the maintenance of increased VEGF and NcVEGF expression after hypoxia. Given the central role of VEGF in major human diseases, including cancer, this novel molecular mechanism is poised to reveal promising possibilities for therapeutic interventions.

Indexed as

Argonaute ProteinsCell HypoxiaCell Line, TumorGene Expression Regulation, NeoplasticHeLa CellsHumansLung NeoplasmsPromoter Regions, GeneticRNA, Double-StrandedRNA, UntranslatedTranscriptional ActivationVascular Endothelial Growth Factor AAGO2 protein, humanArgonaute ProteinsRNA, Double-StrandedRNA, UntranslatedVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID26976645
PMCPMC4859685
OpenAlexW2346261205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.